摘要:
The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
摘要:
The invention provides low-molecular-weight non-sulfated or sulfated exopolysaccharide derivatives prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment (the HE800 strain, a Vibrio diabolicus species of the Vibrio genus), and relates to the use of such low-molecular-weight exopolysaccharide derivatives for the treatment of cancer.
摘要:
The present disclosure relates to a composition for delivery of an anti-cancer agent into a cell, expressing the OAcGD2 ganglioside comprising: (i) at least one anti-cancer agent, and (ii) at least one antibody recognizing the OAcGD2 ganglioside, wherein the at least one antibody recognizing the OAcGD2 ganglioside enhances the uptake of the at least one anti-cancer agent by the tumor cell. The antibody is known and is named the 8B6 antibody. Several variants of the variable claimed, including consensus sequences. Experimental results are provided for a limited number of anti-cancer agents (topotecan, doxorubicin, temozolomide). Combined therapy with said agents show a more potent anti-tumor efficacy.